Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Exagen Inc.NASDAQ: XGN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 23.85M shares rose 28.5% year over year, ahead of the +22.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.5% holds above the trailing-twelve-month pace of +22.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
23.85M+10.7% QoQ
Last fiscal yearDec 2025
21.56M+18.4% YoY
LTMMar 2026
22.36M+22.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.5%——
1 year+18.4%——
3-year CAGR+8.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
21.56M USD
Year-over-year change
+18.4%
4-year CAGR
+7.8%

Weighted Avg Shares (Diluted) vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 weighted avg shares (diluted) of 22.36M shares is the 10th highest of the 11 companies compared; the peer median is 53.17M shares.
  • Its year-over-year change of +22.2% is the 2nd highest of 10, against a peer median of +4.4%.
  • Over three fiscal years its annual growth of +8.1% compares with a peer median of +4.3%.
XGN Competitors Peer median
Weighted Avg Shares (Diluted) for XGN and competitors
Company Period LTM YoY 3-year CAGR
NEONeoGenomics, Inc.LTM Jun 2026129.14M +1.5%+1.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
STXSStereotaxis, Inc.LTM Mar 202693.68M +8.6%+6.1%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
TKNOAlpha Teknova, Inc.LTM Mar 202653.53M +11.4%+24.0%
SGHTSight Sciences, Inc.LTM Mar 202652.81M +4.4%+2.9%
MDXHMDxHealth S.A.FY202550.03M +2.8%+46.6%
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
LFCRLifecore Biomedical, Inc.LTM Mar 202637.34M —+5.7%
XGNExagen Inc.LTM Mar 202622.36M +22.2%+8.1%
SMTISanara MedTech Inc.LTM Mar 20268.79M +3.2%+2.9%
Peer median (excluding XGN) 53.17M+4.4%+4.3%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.3M45.56M52.55M55.64M66.58M
Cost of Revenue20.59M24.21M23.09M22.53M27.78M
Gross Profit27.71M21.35M29.46M33.11M38.8M
Gross Margin57.4%46.9%56.1%59.5%58.3%
Research & Development7.24M9.88M4.87M5.38M6.25M
Selling, General & Admin44.54M52.02M47.43M41.37M46.62M
Operating Expenses51.78M67.4M52.29M46.75M52.87M
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
EBITDA(23.1M)(43.66M)(19.15M)(11.15M)(13.46M)
EBITDA Margin-47.8%-95.8%-36.4%-20.0%-20.2%
Operating Income(24.07M)(46.05M)(22.84M)(13.64M)(14.07M)
Operating Margin-49.8%-101.1%-43.5%-24.5%-21.1%
Interest Income16K830K1.52M767K289K
Interest Expense2.63M2.45M2.34M2.23M4.32M
Other Income / Expenses(2.61M)(1.62M)(819K)(1.47M)(5.83M)
Income Before Tax(26.68M)(47.67M)(23.66M)(15.1M)(19.9M)
Pre-Tax Margin-55.2%-104.6%-45.0%-27.1%-29.9%
Income Tax Expense175K(282K)33K12K51K
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Net Margin-55.6%-104.0%-45.1%-27.2%-30.0%
EPS (Basic)(1.68)(2.77)(1.34)(0.83)(0.93)
EPS (Diluted)(1.68)(2.77)(1.34)(0.83)(0.93)
Weighted Avg Shares15.97M17.08M17.68M18.2M21.56M
Weighted Avg Shares (Diluted)15.97M17.08M17.68M18.2M21.56M

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.